Correlation of somatic mutations and clinical outcome in melanoma patients treated with carboplatin, paclitaxel, and sorafenib

PURPOSE: Sorafenib is an inhibitor of VEGFR, PDGFR, and RAF kinases, amongst others. We assessed the association of somatic mutations with clinicopathologic features and clinical outcomes in patients with metastatic melanoma treated on E2603, comparing treatment with carboplatin, paclitaxel +/− sora...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Wilson, Melissa A., Zhao, Fengmin, Letrero, Richard, D’Andrea, Kurt, Rimm, David L., Kirkwood, John M., Kluger, Harriet M., Lee, Sandra J., Schuchter, Lynn M., Flaherty, Keith T., Nathanson, Katherine L.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4058354/
https://ncbi.nlm.nih.gov/pubmed/24714776
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-0093
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars